Travere Therapeutics' Kidney Disease Drug Falls Short in Trial, Stock Plunges
Travere Therapeutics' kidney disease drug, Filspari, narrowly missed meeting the key endpoint in its confirmatory study, which measured kidney function. Despite this setback, the company still plans to apply for full approval of Filspari in IgA nephropathy next year. The study results will now be evaluated by the FDA, who will decide whether to withdraw the drug. The stock of Travere Therapeutics plummeted following the news.